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Abstract 1 
Background: Previous evidence suggests that delusional disorder has a later 2 
onset and better functional outcomes compared to schizophrenia. However, 3 
studies have not examined longitudinal outcomes in a first episode population, 4 
where confounding factors may be adjusted for.  5 
Methods: A nested case control study was designed within the National EDEN 6 
study; a cohort of 1027 first episode psychosis patients. Patients with a baseline 7 
diagnosis of delusional disorder (n=48) were compared with schizophrenia 8 
(n=262) at 6 and 12 months with respect to symptomatic and functional 9 
outcomes. Regression analysis was used to adjust for possible confounders.   10 
Results: Delusional disorder patients had a shorter duration of untreated 11 
psychosis compared to schizophrenia but were similar in other baseline 12 
characteristics. At baseline, delusional disorder patients had lower symptom 13 
scores but higher function scores compared to those with schizophrenia. At 12 14 
months the differences persisted for symptoms scores but not overall function 15 
scores. After adjusting for baseline score, age and duration of untreated 16 
psychosis, differences between the groups remained significant only for Positive 17 
and Negative Syndrome Scale (PANNS) negative, general and total scores and 18 
recovery rates. There were no differences in changes in outcomes scores.  19 
Conclusions: Delusional disorder in a first episode psychosis population 20 
presents with less severe symptoms, higher recovery rates and better 21 
functioning than schizophrenia, but at 12 months differences are ameliorated 22 
when adjusting for baseline differences.  23 
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intervention; Outcome.  2 
1. Introduction 3 
The validity of delusional disorder as a diagnostic entity separate from 4 
schizophrenia continues to be debated (Hui et al., 2015; Marneros et al., 2012). 5 
Winokur initially refined the description of Kraeplin’s ‘paranoia’ to describe 6 
‘delusional disorder’ (Winokur, 1977),  and in current diagnostic classifications it 7 
occurs as delusional disorder in DSM-V and persistent delusional disorder in 8 
ICD-10. Delusional disorder has an estimated prevalence of around 0.18% in the 9 
general population and between 1-4% of psychiatric inpatient admissions 10 
(Kendler, 1982; Perala et al., 2007), although the true prevalence is likely to be 11 
higher as lack of insight prevents help seeking and recognition of the 12 
illness(Perala et al., 2007).  13 
Despite this, delusional disorder is widely assumed to have favourable functional 14 
outcomes when compared to schizophrenia, despite ongoing delusional 15 
symptoms which can be resistant to treatment (Marneros et al., 2012; 16 
Opjordsmoen, 1988). This often leads to different treatment pathways within 17 
psychiatric services, such as differential prescribing of antipsychotic medication 18 
(Marneros et al., 2012) and service provision (Drake et al., 2000), while 19 
noncompliance and disengagement with services has a detrimental impact on 20 
treatment outcomes (Munro and Mok, 1995). This is further compounded by the 21 
limited high-quality evidence for the effectiveness of treatments for delusional 22 
disorder (Gonzalez-Rodriguez et al., 2016; Manschreck and Khan, 2006; Skelton 23 
et al., 2015).   24 
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However, outcomes in delusional disorder have not been extensively 1 
investigated in a first episode population where differences in symptomatology 2 
and functioning have been more difficult to illicit (Hui et al., 2015). Extant follow-3 
up studies have either been limited by small samples or not considered other 4 
possible confounders in the relationship between diagnosis and outcome. 5 
However, the diagnosis of delusional disorder does appear to have some stability 6 
(Fusar-Poli et al., 2016; Kulkarni et al., 2016; Marneros et al., 2012) although 7 
others continue to question the distinction between delusional disorder and 8 
paranoid schizophrenia (Hui et al., 2015). 9 
The National Eden Study is a database of over 1000 patients admitted to Early 10 
Intervention (EI) services in the UK and provides an excellent opportunity to 11 
investigate the outcome of first episode psychotic disorders in a larger sample 12 
with the ability to adjust for a number of potential confounders in the 13 
relationship between diagnosis and outcome. This study aimed to investigate 6 14 
and 12-month functional and symptomatic outcomes of first episode psychosis 15 
patients who present with a delusional disorder compared to those presenting 16 
with schizophrenia, in order to test the hypothesis that a diagnosis of delusional 17 
disorder leads to improved functional outcomes.  18 
2. Materials and Methods 19 
2.1 Setting 20 
The current study was designed as a nested case-control within the National 21 
EDEN database. The National EDEN study is a longitudinal cohort study 22 
including 1027 first episode psychosis cases admitted to Early Intervention (EI) 23 
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services between August 2005 to April 2009 from in five geographical sites 1 
across England: Birmingham, Cornwall, Cambridge, Norwich and Lancashire 2 
(Birchwood et al., 2014). It aimed to evaluate the implementation and outcomes 3 
of EI services across England. Ethical approval for the cohort study was given by 4 
Suffolk Local Research Ethics Committee, UK. This study investigated those who 5 
received an initial diagnosis of delusional disorder at baseline and compared 6 
them to those with a diagnosis of schizophrenia.  7 
2.2 Participants 8 
The National EDEN study approached all patients referred to EI services in 9 
participating centres between August 2005 and April 2009 for inclusion in the 10 
study. Inclusion criteria were the same as criteria for acceptance into EI services 11 
according to The Department of Health, which is ‘first presentation of psychotic 12 
symptoms between the ages of 14 and 35 years’. The study excluded those with 13 
‘ultra-high risk’ symptoms as they do not meet the criteria for psychosis. Of the 14 
2097 patients that were eligible for inclusion 1027 consented to participate and 15 
were entered into the National EDEN study (49%). 825 patients completed the 6 16 
month follow up and 791 completed 12 month follow up.   17 
Diagnosis was established at baseline entry to the study using the OPCRIT 18 
diagnostic tool (operationalised criteria computerized diagnostic 19 
system)(McGuffin et al., 1991) which generates ICD10 and DSM IV diagnoses 20 
based on analysis of case notes, and has shown good validity and inter-rate 21 
reliability in establishing psychiatric diagnoses (Williams et al., 1996). This study 22 
included those with diagnoses of delusional disorder (n=48) and schizophrenia 23 
(n=262) according to DSM IV made using OPCRIT criteria.  24 
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2.3 Assessments 1 
A number of symptom and functional outcomes were available at 6 and 12-2 
month follow-up in the National EDEN study. This study utilised assessments of; 3 
Positive and Negative Syndrome Scale (PANNS) total, general psychopathology, 4 
negative and positive symptoms(Kay et al., 1987), Young Mania Rating Scale 5 
(YMRS) total score (Young et al., 1978), Calgary Depression Scale for 6 
Schizophrenia total score (Addington et al., 1993), EQ-5D measurement of 7 
health-related quality of life (Brooks, 1996), Global Assessment of Functioning 8 
(GAF) (Jones et al., 1995) symptom, disability and total score. Each of these 9 
scales are frequently used in psychosis research and have well established 10 
validity and reliability (Addington et al., 1992; Brooks, 1996; Jones et al., 1995; 11 
Kay et al., 1989; Young et al., 1978).  12 
Duration of untreated psychosis (DUP) was recorded at baseline along with 13 
other demographic characteristics. DUP was defined as the delay between the 14 
onset of psychosis and the onset of criteria for treatment and was calculated 15 
using a combination of retrospective PANSS assessment, a semi-structured 16 
interview and patient notes (Birchwood et al., 2014).  The onset of psychosis was 17 
considered to have occurred when participants scored 4 or above for one 18 
symptom from the positive scale of the retrospective PANSS, or a cluster of 19 
symptoms including delusions, hallucinations or conceptual disorganisation 20 
which reached a total of 7 or more in the positive subscale. Additionally, these 21 
symptoms had to present for at least 2 weeks.  22 
Additionally, relapse and recovery were assessed using the Bebbington et al 23 
method (Bebbington et al., 2006), which involved a combination of clinical 24 
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interviews and extracting information from case notes to determine changes in 1 
symptoms. Using these criteria, remission can be classified as either full, partial 2 
or absent. If there is no remission, then relapse is recorded as ‘not recovered’. 3 
Relapse can be a type 1 (full), type 2 (exacerbation) or non-recovery. 4 
2.4 Reliability across sites 5 
Research associates were trained in the use of scales such as PANSS, GAF, YMRS, 6 
Calgary Depression Scale, relapse and recovery and DUP assessment. All staff 7 
were required to attend a training programme and new staff were required to 8 
achieve concordance rate of kappa r>0.75 compared to trainers when assessing 9 
tapes of previous interviews. Additionally, every 12 months five DUP 10 
assessments and five relapse and recovery assessments from all sites were 11 
independently assessed for concordance, with kappa r>0.75 required. Every 20th 12 
PANSS assessment was observed by an experienced interviewer for site specific 13 
monitoring, and PANSS reliability was also assessed using a trained rater from 14 
each main site. The average intraclass correlation was 0.90 for positive scale, 15 
0.89 for negative scale and 0.91 for general psychopathology scale. The overall 16 
agreement in relapse categories was 73% (kappa 0.62) with an intraclass 17 
correlation of 0.77 for time to relapse.  18 
2.5 Analysis strategy 19 
All statistical analyses were conducted in IBM SPSS version 24.  The delusional 20 
disorder and schizophrenia groups were compared with respect to baseline 21 
demographics including age, gender, ethnicity, DUP, education level, living 22 
circumstances and occupation. The groups were also compared with respect to 23 
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PANSS, YMRS and Calgary Depression Scale at baseline, 6 months and 12 1 
months, and EQ-5D health thermometer and GAF scores at baseline and at 12 2 
months. Differences between the groups were assessed using the independent 3 
samples t-test for continuous variables and χ2 test for categorical variables. The 4 
level of significance for all testing was set at p<0.05 for all statistical tests. 5 
Regression models were created for each individual outcome of interest as the 6 
independent variable and diagnostic group as the dependent variable. Covariates 7 
included age and DUP, as well as the baseline score for the independent variable 8 
being investigated.  9 
The change in each outcome was also compared between delusional disorder 10 
and schizophrenia groups, using a regression model with change scores as the 11 
independent variable, with diagnostic group as the dependent variable and age 12 
and DUP as covariates. Due to the relatively small number of delusional disorder 13 
patients, ethnicity and gender were not used as covariates in the models due to 14 
over-fitting, (Harrell et al., 1996) and the evidence relating ethnicity to outcome 15 
in psychosis is inconsistent (Chorlton et al., 2012). Regression models were 16 
created for change in PANSS, YMRS and Calgary Depression Scale at 6 and 12 17 
months, and for EQ-5D health thermometer and GAF at 12 months follow up.  18 
3. Results 19 
3.1 Sample information 20 
Of the 815 patients with diagnostic information, a total of 48 patients with a 21 
diagnosis of delusional disorder and 262 patients with a diagnosis of 22 
schizophrenia according to DSM IV were included in this study. However, the 23 
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number of patients that provided information for each assessment varied, and 1 
the specific numbers of participants in each analysis are shown in tables 1, 2 and 2 
3.  3 
3.2 Baseline demographics 4 
The were no differences in age of onset, gender or ethnicity between patients 5 
with delusional disorder and schizophrenia (table 1). There were no overall 6 
differences in educational level, living circumstances or occupational 7 
circumstances between the groups, although when examined on a pairwise basis 8 
a significantly larger proportion of those with delusional disorder were in paid 9 
employment (29.8%) compared to those with schizophrenia (13%) p=0.004. 10 
Mean DUP was also significantly shorter in delusional disorder (135.8 days, 95% 11 
CI 66.5-205.1) compared to schizophrenia (330.2 days, 95% CI 248.8-411.7) 12 
p<0.001. There was no difference in lifetime history of substance misuse 13 
between the groups (table 2).  14 
3.3 Baseline symptoms and function 15 
Baseline PANSS, YMRS, Calgary Depression Scale, EQ-5D and GAF scores for each 16 
group are shown in table 2. The delusional disorder group had significantly 17 
better functioning at baseline in terms of GAF total (delusional disorder mean 18 
52.88 95% CI 47.31-58.45, schizophrenia mean 46.89 95% CI 44.77-49.01, 19 
p=0.036), GAF symptom (delusional disorder mean 55.47 95% CI 50.02-60.91, 20 
schizophrenia mean 48.85 95% CI 46.71-50.98, p=0.02) and GAF disability 21 
scores (delusional disorder mean 58.61 95% CI 53.58-63.64, schizophrenia 22 
mean 48.7 95% CI 46.75-50.68, p<0.001) compared to the schizophrenia group. 23 
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PANSS mean scores were also significantly lower for the delusional disorder 1 
group compared to schizophrenia, in positive (delusional disorder 14.44 95% CI 2 
12.70-16.19, schizophrenia 16.75 95% CI 15.96-17.55, p=0.023), negative 3 
(delusional disorder 13.26 95% CI 11.26-15.25, schizophrenia 16.09 95% CI 4 
15.28-16.9, p=0.008), general psychopathology (delusional disorder 30.62 95% 5 
CI 27.5-33.75, schizophrenia 34.01 95% CI 32.68-35.35, p=0.049) and total 6 
(delusional disorder 58.14 95% CI 51.9-64.38, schizophrenia 66.23 95% CI 7 
63.88-68.58, p=0.009) subsection mean scores. There were no differences in 8 
YMRS, Calgary depression or EQ-5D health thermometer mean scores between 9 
the two groups.  10 
3.4 6 and 12 months follow up symptoms and functioning 11 
As shown in table 3, at 6 months the delusional disorder group has significantly 12 
lower PANSS mean scores than the schizophrenia group in positive (delusional 13 
disorder 9.92 95% CI 8.88-10.96, schizophrenia 12.65 95% CI 11.94-13.36, 14 
p<0.001), negative (delusional disorder 10.95 95% CI 9.70-12.20, schizophrenia 15 
14.44 95% CI 13.62-15.26, p<0.001), general (delusional disorder 24.66 95% CI 16 
22.40-26.92, schizophrenia 28.12 95% CI 26.95-29.28, p=0.017) and total 17 
(delusional disorder 45.53 95% CI 41.66-49.39, schizophrenia 55.01 95% CI 18 
52.75-57.27, p<0.001) subsection mean scores. Additionally, delusional disorder 19 
patients had significantly lower YMRS mean scores (delusional disorder 2.0 95% 20 
CI 1.07-2.93, schizophrenia 4.15 95% CI 3.39-4.90, p=0.001), although Calgary 21 
Depression Scale mean scores were not different between the groups.  22 
As shown in table 3, at 12 months the delusional disorder group continued to 23 
have lower PANSS mean scores than the schizophrenia group in positive 24 
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(delusional disorder 10.26 95% CI 9.07-11.44, schizophrenia 12.07 95% CI 1 
11.38-12.77, p=0.01), negative (delusional disorder 10.69 95% CI 9.56-11.83, 2 
schizophrenia 13.39 95% CI 12.57-14.21, p<0.001), general (delusional disorder 3 
23.11 95% CI 20.97-25.24, schizophrenia 26.82 95% CI 25.60-28.04, p=0.014) 4 
and total (delusional disorder 44.13 95% CI 40.29-47.97, schizophrenia 52.24 5 
95% CI 49.84-54.64, p=0.001) subsection mean scores. Baseline, 6 and 12 month 6 
PANSS subsection mean scores are shown in figure 1. Additionally, patients with 7 
delusional disorder continued to have significantly better functioning in terms of 8 
GAF symptoms (delusional disorder mean 67.79 95% CI 63.18-72.40 9 
schizophrenia mean 61.56 95% CI 59.16-63.96, p=0.042) and disability scores 10 
(delusional disorder mean 68.24 95% CI 62.91-73.56, schizophrenia mean 59.29 11 
95% CI 56.93-61.66, p=0.004), although the difference in GAF total score failed 12 
to reach significance at the 0.05 level (delusional disorder mean 66.53 95% CI 13 
61.01-72.04, schizophrenia mean 60.43 95% CI 57.93-62.93, p=0.056). Baseline, 14 
6 and 12 month GAF mean scores are shown in figure 2. There was no difference 15 
at 12 months between the groups in YMRS, Calgary Depression Scale or EQ-5D 16 
health thermometer mean scores. There was also no difference in the number of 17 
patients who received antipsychotic treatment at 12 months. Relapse rates did 18 
not differ between the groups, although a significant difference was seen in 19 
recovery rates with 72.3% of those with delusional disorder achieving full 20 
recovery compared to 47.9% with schizophrenia, and only 2.1% of those with 21 
delusional disorder failing to achieve recovery compared to 14% with 22 
schizophrenia (p=0.004).  23 
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At 12 months the delusional disorder group continued to have a significantly 1 
larger proportion paid employment (27.1%) compared to those with 2 
schizophrenia (12.6%) p=0.009.  3 
3.5 Adjusted analysis at 6 and 12 months 4 
Due to evidence of skew with data, 6 and 12 month outcomes underwent log 5 
transformation prior to adjustment using regression models. The adjusted 6 
analysis with each of the assessment outcomes as the independent variable is 7 
shown in table 3.  8 
Once adjusted for the corresponding baseline score, DUP and age the delusional 9 
disorder group still had significantly lower PANSS positive (p=0.022) negative 10 
(p=0.011), and total (p=0.022) scores compared to the schizophrenia group at 6 11 
months. There was no significant difference between the groups for PANSS 12 
general scores, YMRS or Calgary Depression Scale at 6 months follow up.  13 
At 12 months follow up the delusional disorder group had significantly lower 14 
PANSS negative (p=0.045), general (p=0.032) and total (p=0.040) scores 15 
compared to the schizophrenia group when adjusted for baseline score, DUP and 16 
age. In the adjusted analysis there was no significant difference between the 17 
groups for PANSS positive scores, YMRS, Calgary Depression Scale, EQ-5D health 18 
thermometer or any subsection of GAF scores. Once adjusted for age and DUP 19 
the delusional disorder group continued to have significantly higher rates of 20 
recovery (p=0.002), but there was no difference between the groups for relapse 21 
at 12 months.  22 
3.6 Analysis of change scores 23 
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The delusional disorder and schizophrenia groups were also compared with 1 
respect to the change in each outcome from baseline to the 6 and12 month 2 
assessment (table 3). There were no significant differences between the groups 3 
in the mean change in each outcome from baseline to either 6 or 12 months (data 4 
not shown). Once adjusted  using a regression model with DUP and age of onset 5 
entered as covariates, there remained no significant differences in the change 6 
scores for any outcome between the groups at either 6 or 12 months follow up.  7 
4. Discussion 8 
4.1 Summary and interpretation of the results 9 
This nested case control used data from The National EDEN study to compare 10 
patients with a diagnosis of delusional disorder to those with schizophrenia and 11 
assess differences in outcomes at 6 and 12 months. This is the first study that the 12 
authors are aware of to compare outcomes of first episode delusional disorder 13 
and schizophrenia patients in a longitudinal follow up study.  14 
This study found that patients with a diagnosis of delusional disorder have 15 
better functioning and less severe symptomatology at initial presentation, which 16 
mostly persisted at 6 and 12 months follow up. After adjusting for age and DUP, 17 
patients with delusional disorder did not demonstrate any differences in 18 
functioning scores compared to the schizophrenia diagnosis group. This may 19 
suggest that factors such as age of onset and DUP are the determinants of 20 
functional outcome, rather than the diagnosis of delusional disorder itself.  21 
At 6 month follow up less severe positive and negative symptoms were 22 
independently related to a diagnosis of delusional disorder, although the 23 
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difference in positive symptoms scores did not persist at 12 months, possibly as 1 
the schizophrenia group continued to improve in this domain from 6 to 12 2 
months. The only 12 month outcomes that appeared to be independently related 3 
to a diagnosis of delusional disorder were negative and general psychopathology 4 
and total PANSS score.  This contrasts with some previous studies of patients 5 
with delusional disorder, which have generally found that they have improved 6 
functional outcomes compared to schizophrenia patients (Opjordsmoen, 1988), 7 
as well as less severe psychopathology (Marneros et al., 2012).  However, this 8 
study did find that those with delusional disorder had significantly higher rates 9 
of recovery than those with schizophrenia, which remained significant after 10 
adjusting for baseline characteristics. As the definition of recovery is based on 11 
symptoms and correlates well with PANSS scores (Bebbington et al., 2006), this 12 
likely reflects the less severe psychopathology in the delusional disorder group.   13 
There were no differences between schizophrenia and delusional disorder when 14 
looking at changes in the outcome scores, although both groups improved over 15 
12 months on both symptom and function scores. This appears to suggest that 16 
while patients with delusional disorder may present with a less severe illness 17 
form,  both groups showed similar symptomatic and functional improvement in 18 
the short term. 19 
Another interesting finding was the significantly shorter DUP in patients with 20 
delusional disorder compared to schizophrenia. This is contrary to what has 21 
been previously been suggested for delusional disorder, as it is often thought 22 
that due to less severe illness, better functioning and poor insight patients 23 
frequently delay help seeking (or others seek help for them) and therefore have 24 
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longer DUP (Ibanez-Casas and Cervilla, 2012). Notwithstanding this, other 1 
studies have shown similar (González-Rodríguez et al., 2015) or slightly shorter 2 
DUP in patients with delusional disorder (Hui et al., 2015). The shorter DUP in 3 
the delusional disorder patients in this cohort may explain the improved 4 
functioning found in the unadjusted 12 month outcomes shown above.  5 
The use of a cohort of first episode psychosis patients may explain some of the 6 
differences compared with previous studies into delusional disorder. Previous 7 
studies investigating delusional disorder patients have found an older age of 8 
onset compared to schizophrenia (Marneros et al., 2012; Opjordsmoen, 1988), 9 
and may present more frequently around middle age (Manschreck and Khan, 10 
2006). The mean age of onset in this study was almost identical for both groups 11 
(21.3 and 21.7 years for schizophrenia and delusional disorder respectively) and 12 
considerably younger than previously reported for delusional disorder. All 13 
patients in this study were referred to EI services, which at this time in the UK 14 
treated patients aged 18-35 years, and therefore a significantly older age group 15 
was de facto excluded. Patients in this study also showed a significant male 16 
predominance, and while this has been reported previously (Opjordsmoen, 17 
1988; Opjordsmoen and Retterstol, 1991; Winokur, 1977), the proportion of 18 
81% male is particularly high. Therefore, it may be that early onset delusional 19 
disorder patients have a different demographics, poorer functioning and worse 20 
prognosis to the ‘traditional’ later onset delusional disorder, and instead present 21 
more similarly to schizophrenia, albeit with a milder illness form. On the other 22 
hand, the presentation of delusional disorder at an earlier stage may have a 23 
significant effect on social integration, education and occupational activities, and 24 
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therefore these patients end up with poorer functioning as a result of the earlier 1 
presentation.  2 
4.2 Strengths and Limitations 3 
This study included a large cohort of patients with first episode delusional 4 
disorder and schizophrenia patients, with systematic, reliable assessments of 5 
diagnosis, symptomatology and functioning, and naturalistic 12 month follow up. 6 
This allowed for adjustment in a number of confounding factors when 7 
investigating outcomes. Despite these strengths, there are a number of 8 
limitations that need to be considered when interpreting the findings. At present 9 
the follow up data for the National EDEN study is only available up to 12 months, 10 
and short-term outcome measurements may not be sufficient to detect any 11 
divergence in the illness course of delusional disorder from schizophrenia which 12 
has been shown previously (Marneros et al., 2012; Opjordsmoen, 1988). There 13 
were some missing data and 6 and 12 month follow up points for both groups 14 
and the specific numbers for each outcome are detailed in table 3, but these were 15 
relatively modest and therefore missing data analysis was not performed.  16 
Furthermore, diagnosis was assessed using OPCRIT diagnostic tool, which is not 17 
a gold standard structured clinical interview. This diagnosis was not reassessed 18 
at the 12 month follow up point, and therefore it is not possible to tell if there 19 
was some diagnostic shift between groups. Notwithstanding, a diagnosis of 20 
delusional disorder at first presentation has been shown to have diagnostic 21 
stability over time (Fusar-Poli et al., 2016; Marneros et al., 2012). Previous 22 
studies have also found differences in the nature of delusions experienced 23 
between delusional disorder and schizophrenia, and while detailed information 24 
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was available for PANSS scores, details on specific psychotic symptoms, such as 1 
first rank symptoms and the nature of delusions were not assessed in this cohort.  2 
Another possible explanation for the differences between this cohort and 3 
previous studies investigating later onset delusional disorder is that many 4 
patients with less severe symptoms who function well in the community may not 5 
may never be referred to EI services. Such patients may only come to attention of 6 
mental health teams when there is an issue of risk or life stressors affect their 7 
ability to function, and may therefore present later in life.   8 
While DUP was carefully defined and calculated from historical information, 9 
accurate measurement remains difficult, especially so in delusional disorder 10 
(Compton et al., 2007).  Finally, while every effort was made to adjust for 11 
confounding factors that are known to influence outcome and prognosis in 12 
psychotic illnesses, there may be further unknown factors which affect outcome 13 
which we have not adjusted for.  14 
4.3 Clinical Implications 15 
This study suggests that patients presenting with a first episode delusional 16 
disorder have less severe symptomatology and better functioning at baseline 17 
compared to patients presenting with first episode schizophrenia. The majority 18 
of these differences persisted at 12 months follow up, although after adjusting 19 
for confounding factors only PANSS negative and general scores were 20 
significantly lower in the delusional disorder group, while schizophrenia 21 
patients had lower rates of recovery. However, it could be considered that 22 
baseline differences in the two groups such as age of onset and DUP are inherent 23 
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characteristics of the diagnostic group rather than confounders. Therefore, the 1 
unadjusted scores presented here should be considered as relevant to the 2 
prognosis of delusional disorder in first episode patients. Nonetheless, the 3 
differences in the adjusted scores demonstrates that early age of onset and 4 
longer DUP still act as negative prognostic factors for those with delusional 5 
disorder, leading to poorer functioning.    6 
There were no differences in the change in outcome scores between the groups, 7 
which suggests that both groups appeared to improve to a similar degree over 8 
12 month follow up.  9 
There has been much debate in literature as to the existence of delusional 10 
disorder as a separate diagnostic entity that is different to schizophrenia (Hui et 11 
al., 2015; Marneros et al., 2012; Opjordsmoen and Retterstol, 1991). This study 12 
adds a unique insight into this debate by reporting on a cohort of first episode 13 
delusional disorder patients with a younger age of onset. Previous studies of 14 
delusional disorder reporting improved functional outcomes have suggested that 15 
delusional disorder has an older age of onset than schizophrenia (Kendler, 1982; 16 
Manschreck and Khan, 2006; Marneros et al., 2012; Winokur, 1977). This may 17 
not be directly comparable to the younger onset delusional disorder patients 18 
described here, who appear to present with a shorter DUP, better baseline 19 
functioning and fewer symptoms than patients with schizophrenia, but little 20 
difference in the course of the illness over 12 months. Further studies are 21 
required to determine if there are differences in functional outcomes between 22 
early and late onset delusional disorder.  23 
20 
 
Recent studies have suggested a dimensional concept of psychoses, and that 1 
delusional disorder could be viewed as a ‘partial psychoses’, with fewer negative 2 
symptoms than schizophrenia and fewer affective symptoms than schizoaffective 3 
disorder (Munoz-Negro et al., 2015; Opjordsmoen, 2014). This study may 4 
support this approach. Clinically this suggests that although delusional disorder 5 
patients present with less severe illness than schizophrenia, EI services should 6 
treat these patients similarly, as current evidence suggests they do respond to 7 
antipsychotic treatment (Gonzalez-Rodriguez et al., 2016; Manschreck and Khan, 8 
2006) and patients demonstrate improvement similar to that seen in 9 
schizophrenia. Further follow up studies are required to determine whether 10 
younger onset delusional disorder patients retain their diagnosis over time, and 11 
whether illness courses diverge from schizophrenia in the longer term.  12 
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Figure Legends 12 
Figure 1: Mean PANSS positive, negative, general and total scores at baseline, 6 13 
months and 12 months for delusional disorder and schizophrenia groups. 14 
Figure 2: Mean GAF total, symptom and disability scores at baseline and 12 15 
months for delusional disorder and schizophrenia groups. 16 
 17 
Table 1: Baseline demographics and substance use of the sample by diagnostic 18 
group 19 
 Schizophrenia* 
 
Delusional 
disorder * 
Total* P value 
Age at onset 
N total 
Mean (SD) 
95% CI 
 
252 
21.28 (4.95) 
(20.66, 21.89) 
 
47 
21.68 (4.86) 
(20.26, 23.11) 
 
299 
21.34 
(20.78, 21.9) 
0.607 
Gender  
N total 
Male (%) 
 
262 
191 (72.9) 
 
48 
39 (81.3) 
 
310 
230 (74.2) 
0.224 
25 
 
DUP  
N total 
Mean (SD) 
95% CI 
 
258 
330.26 (664.4) 
(248.81, 411.72) 
 
47 
135.79 (236.1) 
(66.46, 205.12) 
 
305 
300.3 (621.8) 
(230.24, 370.35) 
<0.001 
Educational level/Qualifications  
N total (%) 
None 
Basic (GCSE/NVQ ½) 
Advanced (A level/BTEC/NVQ3) 
Degree/HND/NVQ 4+ 
Special needs educational 
qualifications 
 
257 
71 (27.6%) 
111 (43.2%) 
58 (22.6%) 
16 (6.2%) 
1 (0.4%) 
 
47 
7 (14.9%) 
23 (48.9%) 
11 (23.4%) 
5 (10.6%) 
1 (2.1%) 
 
304 
78 (25.7%) 
134 (44.1%) 
69 (22.7%) 
21 (6.9%) 
2 (0.7%) 
0.217 
Ethnicity 
N total 
Asian 
Black 
Caucasian 
Mixed 
Other 
 
262 
49 (18.7%) 
23 (8.8%) 
172 (65.6%) 
15 (5.7%) 
3 (1.1%) 
 
48 
3 (6.3%) 
5 (10.4%) 
36 (75%) 
4 (8.3%) 
0 (0%) 
 
310 
52 (16.8%) 
28 (9%) 
208 (67.1%) 
19 (6.1%) 
3 (1%) 
0.249 
Living circumstances 
N total 
Alone 
With parents/guardians 
With partner 
Other 
 
260 
39 (15%) 
171 (65.8%) 
16 (6.2%) 
34 (13.1%) 
 
48 
10 (20.8%) 
26 (54.2%) 
4 (8.3%) 
8 (16.7%) 
 
308 
49 (15.9%) 
197 (64.0%) 
20 (6.5%) 
42 (13.6%) 
0.494 
Occupational circumstances 
N total 
Working (paid) 
Working (voluntary) 
Unemployed 
Homemaker 
Student 
Other 
 
261 
34 (13%) 
4 (1.5%) 
178 (68.2%) 
6 (2.3%) 
37 (14.2%) 
2 (0.8%) 
 
47 
14 (29.8%) 
0 (0%) 
28 (59.6%) 
1 (2.1%) 
4 (8.5%) 
0 (0%) 
 
308 
48 (15.6%) 
4 (1.3%) 
206 (66.9%) 
7 (2.3%) 
41 (13.3%) 
2 (0.6%) 
0.085 
DUP, duration of untreated psychosis; GCSE, General Certificate of Secondary Education; NVQ, National 1 
Vocational Qualification; BTEC, Business and Technology Educational Council; HND, Higher National 2 
Diploma. 3 
P-values in bold indicate significance at the <0.05 level.  4 
 5 
Table 2: Baseline symptoms and functioning scores by diagnostic group 6 
  Schizophrenia*  Delusional 
disorder* 
Total* Mean 
difference 
P value 
PANSS 
positive  
N  
Mean score (SD) 
95% CI 
244 
16.75 (6.32) 
(15.96, 17.55) 
45 
14.44 (5.81) 
(12.70, 
16.19) 
289 
16.39 (6.29) 
(15.67, 
17.12) 
 
2.31 
(0.31, 4.31) 
0.023 
PANSS 
negative  
N  
Mean score (SD) 
95% CI 
241 
16.09 (6.38) 
(15.28, 16.9) 
43 
13.26 (6.5) 
(11.26, 
15.25) 
284 
15.66 (6.46) 
(14.91, 
16.42) 
 
2.84 
(0.75, 4.92) 
0.008 
PANSS 
general  
N  
Mean score (SD) 
95% CI 
244 
34.01 (10.58) 
(32.68, 35.35) 
45 
30.62 (10.41) 
(27.5, 33.75) 
289 
33.48 (10.61) 
(32.26, 
34.71) 
 
3.39 
(0.02, 6.76) 
0.049 
PANSS total  N  
Mean score (SD) 
95% CI 
237 
66.23 (18.38) 
(63.88, 68.58) 
43 
58.14 (20.28) 
(51.9, 64.38) 
280 
64.99 (18.87) 
(62.77, 
67.21) 
 
8.09 
(1.99, 
14.18) 
0.009 
26 
 
Calgary 
Depression 
Scale 
N  
Mean score (SD) 
95% CI 
245 
5.46 (5.17) 
(4.81, 6.11) 
44 
5.95 (5.4) 
(4.31, 7.6) 
289 
5.54 (5.20) 
(4.93, 6.14) 
 
-0.49 
(-2.17, 
1.18) 
0.563 
YMRS  N  
Mean score (SD) 
95% CI 
244 
6.78 (7.30) 
(5.86, 7.7) 
42 
5.36 (8.0) 
(2.88, 7.84) 
286 
6.57 (7.40) 
(5.71, 7.44) 
 
1.43 
(-1.01, 
3.86) 
0.250 
GAF total  N  
Mean score (SD) 
95% CI 
248 
46.89 (16.96) 
(44.77, 49.01) 
42 
52.88 (17.88) 
(47.31, 
58.45) 
290 
47.76 (17.20) 
(45.77, 
49.74) 
 
-5.99 
(-11.61, -
0.38) 
0.036 
GAF 
symptoms  
N  
Mean score (SD) 
95% CI 
246 
48.85 (17.00) 
(46.71, 50.98) 
43 
55.47 (17.70) 
(50.02, 
60.91) 
289 
49.83 (17.24) 
(47.83, 
51.83) 
 
-6.62 
(-12.18, -
1.06) 
0.020 
GAF 
disability  
N  
Mean score (SD) 
95% CI 
247 
48.70 (15.70) 
(46.75, 50.68) 
41 
58.61 (15.90) 
(53.58, 
63.64) 
288 
50.13 (16.08) 
(48.26, 
51.99) 
 
-9.89 
(-15.11, -
4.67) 
<0.001 
EQ-5D 
health 
thermomet
er 
N  
Mean score (SD) 
95% CI 
227 
61.63 (22.36) 
(58.70, 64.55) 
36 
60.00 (24.11) 
(51.84, 
68.16) 
263 
61.40 
(58.66, 
64.14) 
 
1.63 
(-6.36, 
9.61) 
0.689 
Lifetime 
substance 
use 
(n=297)  
Yes  
No 
176 
74 
32 
15 
208 
89 
 0.751 
*overall N for Delusional Disorder = 48, for schizophrenia = 262 and total = 310, number vary slightly by 1 
individual symptom outcome 2 
Footnote: GAF= Global Assessment of Functioning scale; YMRS= Young Mania Rating Scale; PANSS= Positive 3 
and Negative Syndrome Scale; EQ= EuroQol 4 
P-values in bold indicate significance at the <0.05 level.  5 
  6 
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Table 3: 6 and 12 month symptom and functional outcomes for Delusional Disorder and Schizophrenia unadjusted and adjusted for 
baseline score, DUP and age after natural log transformation 
  Unadjusted 6 month outcomes Adjusted 6 month 
outcomes* 
6 month change 
scores 
Unadjusted 12 month outcomes Adjusted 12 month 
outcomes* 
 
12 month 
change score 
 
  Schizophrenia Delusional 
disorder 
P 
value 
P value Beta P 
value 
Beta Schizophrenia Delusional 
disorder 
P 
value 
P value Beta P 
value 
Beta 
PANSS positive N 
Mean  
95% 
CI 
201 
12.65 
 
(11.94, 13.36) 
38 
9.92 
 
(8.88, 10.96) 
<0.001 0.022 -0.142 0.389 -0.060 205 
12.07 
(11.38, 12.77) 
39 
10.26 
(9.07, 11.44) 
0.010 0.127 -0.099 0.859 0.012 
PANSS negative N 
Mean  
95% 
CI 
199 
14.44 
 
(13.62, 15.26) 
38 
10.95 
 
(9.70, 12.20) 
<0.001 0.011 -0.147 0.371 -0.063 203 
13.39 
(12.57, 14.21) 
39 
10.69 
(9.56, 11.83) 
<0.001 0.045 -0.132 0.784 -0.019 
PANSS general N 
Mean  
95% 
CI 
200 
28.12 
(26.95, 29.28) 
38 
24.66 
(22.40, 26.92) 
0.017 0.161 -0.090 0.689 -0.028 205 
26.82 
(25.60, 28.04) 
38 
23.11 
(20.97, 25.24) 
0.014 0.032 -0.138 0.466 -0.049 
PANSS total  N 
Mean  
95% 
CI 
198 
55.01 
(52.75, 57.27) 
38 
45.53 
(41.66, 49.39) 
<0.001 0.022 -0.139 0.442 -0.054 203 
52.24 
(49.84, 54.64) 
38 
44.13 
(40.29, 47.97) 
0.001 0.040 -0.134 0.766 -0.021 
Calgary 
Depression Scale 
N 
Mean  
95% 
CI 
208 
3.80 
(3.19, 4.42) 
38 
3.79 
(2.38, 5.19) 
0.986 0.462 0.056 0.767 -0.027 204 
3.11 
(2.56, 3.67) 
38 
2.21 
(0.94, 3.49) 
0.202 0.701 -0.032 0.134 -0.137 
YMRS N 
Mean  
95% 
CI 
211 
4.15 
(3.39, 4.90) 
37 
2.00 
(1.07, 2.93) 
0.010 0.528 -0.020   206 
3.79 
(3.07, 4.50) 
39 
2.95 
(1.39, 4.51) 
0.351 0.979 0.002 0.572 0.057 
GAF total N 
Mean  
95% 
CI 
       217 
60.43 
(57.93, 62.93) 
40 
66.53 
(61.01, 72.04) 
0.056 0.179 0.085 0.906 0.008 
28 
 
GAF symptoms N 
Mean  
95% 
CI 
       214 
61.56 
(59.16, 63.96) 
38 
67.79 
(63.18, 72.40) 
0.042 0.070 0.112 0.826 0.015 
GAF disability N 
Mean  
95% 
CI 
       214 
59.29 
(56.93, 61.66) 
38 
68.24 
(62.91, 73.56) 
0.004 0.083 0.111 0.821 -0.015 
EQ5D health 
thermometer 
N 
Mean  
95% 
CI 
       182 
66.03 
(62.81, 69.25) 
34 
68.79 
(60.78, 76.81) 
0.505 0.301 0.074 0.285 0.081 
Relapse (%)              
None 
Type 2 
exacerbation 
Type 1 true 
         
145 (66.5%) 
47 (21.6%) 
26 (11.9%) 
 
34 (77.3%) 
8 (18.2%) 
2 (4.5%) 
 
0.261 
 
 
0.106 
   
Recovery (%)       
None                                
Partial  
Full 
         
36 (14.0%) 
98 (38.1%) 
123 (47.9%) 
 
1 (2.1%) 
12 (25.5%) 
34 (72.3%) 
 
0.004 
 
0.002 
   
Antipsychotic 
treatment (%) 
N=310 
        34 (13%) 9 (18.8%) 0.287     
*adjusted analysis with DUP (Duration of Untreated Psychosis), age and baseline scores as covariates, apart from the analyses for relapse and recovery when baseline scores were not 
a covariate 
Footnote: GAF= Global Assessment of Functioning scale; YMRS= Young Mania Rating Scale; PANSS= Positive and Negative Syndrome Scale; EQ= EuroQol 
P-values in bold indicate significance at the <0.05 level.  
 
 
 
 
